EV71 virus-like particles produced by co-expression of capsid proteins in yeast cells elicit humoral protective response against EV71 lethal challenge

• Published in: BMC research notes 2016-01, Vol.9 (1), p.42-42, Article 42
• Main Authors: Wang, Xiaowen, Xiao, Xiangqian, Zhao, Miao, Liu, Wei, Pang, Lin, Sun, Xin, Cen, Shan, Yang, Burton B, Huang, Yuming, Sheng, Wang, Zeng, Yi
• Format: Article
• Language: English
• Subjects: Animals; Animals, Newborn; Antibodies, Neutralizing - biosynthesis; Antibodies, Viral - biosynthesis; Capsid Proteins - administration & dosage; Capsid Proteins - genetics; Capsid Proteins - immunology; Disease Models, Animal; Enterovirus A, Human - drug effects; Enterovirus A, Human - growth & development; Enterovirus A, Human - immunology; Female; Gene Expression; Hand, Foot and Mouth Disease - immunology; Hand, Foot and Mouth Disease - prevention & control; Hand, Foot and Mouth Disease - virology; Immunity, Humoral - drug effects; Mice; Mice, Inbred BALB C; Neutralization Tests; Plasmids - chemistry; Plasmids - immunology; Protein Isoforms - administration & dosage; Protein Isoforms - genetics; Protein Isoforms - immunology; Recombinant Proteins - administration & dosage; Recombinant Proteins - genetics; Recombinant Proteins - immunology; Saccharomyces cerevisiae - genetics; Saccharomyces cerevisiae - metabolism; Vaccination; Vaccines, Virus-Like Particle - administration & dosage; Vaccines, Virus-Like Particle - genetics; Vaccines, Virus-Like Particle - immunology; Viral Vaccines - administration & dosage; Viral Vaccines - genetics; Viral Vaccines - immunology
• ISSN: 1756-0500; 1756-0500
• DOI: 10.1186/s13104-015-1780-x

Enterovirus 71 (EV71) is the most common causative pathogens of hand, foot and mouth disease (HFMD) associated with severe neurological complications. There is a great need to develop prophylactic vaccine against EV71 infection. EV71 virus-like particle (VLP) was produced in yeast expression system by the co-expression of four EV71 structural proteins VP1-VP4. Immunization with the recombinant VLPs elicited potent anti-EV71 antibody responses in adult mice and anti-VLP sera were able to neutralize EV71 virus in vitro. Neonatal mice model demonstrated VLP immunization conferred protection to suckling mice against the lethal viral challenge. Co-expression of four EV71 structural proteins VP1-VP4 in yeast expression systems is an effective method to produce EV71 VLPs. VLP-based vaccine shows great potential to prevent EV71 infection.